Expert Guidance on Treatment Advances in Acute Myeloid Leukemia

Join expert faculty in this interactive 1-hour workshop examining optimal treatment approaches for your patients with acute myeloid leukemia.


Clinical Discussion 1: Selecting Therapy for AML Without Predictive Biomarkers or Therapeutically Actionable Genomic or Molecular Alterations

Clinical Discussion 2: Selecting Therapy for AML With Predictive Biomarkers or Therapeutically Actionable Genomic or Molecular Alterations

Clinical Discussion 3: New and Novel Advances in AML Therapeutics—Future Approaches to BMT and Targeted Therapies 


Date / Time
Event Details


Program Director
Amir T. Fathi, MD

Director, Leukemia Program
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Program Director
Eunice S. Wang, MD

Professor of Oncology
Chief, Leukemia Service
Department of Medicine
Roswell Park Comprehensive Cancer Center
Buffalo, New York

Naval G. Daver, MD

Associate Professor
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas

Brian Jonas, MD

Associate Professor of Medicine
Division of Hematology and Oncology
University of California, Davis School of Medicine
Sacramento, California

Thomas LeBlanc, MD

Associate Professor of Medicine
Associate Professor in Population Health Sciences

Duke University School of Medicine
Duke Cancer Institute
Durham, North Carolina

Gail J. Roboz, MD

Director, Clinical and Translational Leukemia Programs
Professor of Medicine
Weill Cornell Medicine
The New York Presbyterian Hospital
New York, New York

Gary J. Schiller, MD

Division of Hematology/Oncology
Department of Medicine
Director, Hematological Malignancy/Stem Cell Transplantation
David Geffen School of Medicine at UCLA
Los Angeles, California

Goal Statement
The goal of this activity is to improve the knowledge, confidence, competence, and performance of learners in integrating the most up to date guidelines and expert consensus into the care of their patients with AML.

Target Audience
This program is intended for physicians, nurses, pharmacists, and other healthcare professionals who care for patients AML.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Evaluate the clinical data on prognostic or predictive molecular features or aberrations in AML and describe their clinical importance in terms of diagnosis, risk prediction, assessment of measurable residual disease, and therapeutic decisions
  • Plan evidence-based therapeutic strategies for older unfit patients, those with preexisting comorbidities, and/or those with secondary AML using novel targeted agents or formulations and refinements of conventional chemotherapy
  • Select optimal maintenance treatment following induction therapy for patients who are not candidates for, or who choose not to proceed to, hematopoietic stem cell transplantation
  • Develop personalized treatment plans for patients with newly diagnosed or relapsed/refractory AML with FLT3 or IDH1/2 mutations or positive for CD33
  • Assess the available evidence to optimally integrate immunotherapeutic agents, including monoclonal antibody–based therapy, immune checkpoint inhibitors, vaccines, and adoptive cell–based therapy
  • Address patient-specific challenges surrounding pre- and posttransplant processes and novel agents to mitigate risk
  • Manage treatment-related toxicities associated with novel therapeutics


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Designation of Credit

CCO designates this live activity or enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Continuing Pharmacy Education

CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-21-146-L01-P

Type of Activity: Knowledge

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.